Donald Coppen PhD MBA        

Donald is an experienced business development & alliance management executive of 15 years experience across the medtech, biotech & pharma sectors specialising in:

• Conducting market research & drafting business plans;
• Leading in-/out-licensing & acquisition activities;
• Negotiating partnering & distribution agreements, and;
• Managing key strategic partners.

Currently he is a consultant at Sitatunga Ltd. Previously he was Director of Business Development & Alliance Management at the Norwegian biotech Algeta ASA, both managing the $800m Bayer alliance as the company's lead oncology drug Xofigo transitioned from clinical development through to commercial launch, and seeking new product opportunities until Bayer's $2.9B acquisition of Algeta. Prior to this he was the Director of Business Development at Biocompatibles plc and responsible for partnering/ licensing the company's diverse range of pre-/clinical & marketed medtech/ biotech & cell therapy products across oncology, neurology & diabetes until it was acquired by BTG plc for £177m. Earlier roles included programme management at Lonza Biologics and product & regulatory roles with American Cyanamid at their international base in Belgium.

Donald has a PhD in Applied Biology from the University of Southampton, a MBA from the Cranfield School of Management and has recently qualified as a rugby referee with the RFU.

Funding Partners: